Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully ...
There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.
As we have entered into the new year 2025, here's a recap of 2024's economy and healthcare with key areas to look in global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback